Phreesia Announces Fiscal Third Quarter 2022 Results

·18 min read

RALEIGH, N.C., December 08, 2021--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) ("Phreesia") announced financial results today for the fiscal third quarter ended October 31, 2021.

"We celebrated an important milestone in September as we surpassed 100 million patient visits enabled by our platform during the previous twelve months", said CEO and Co-Founder Chaim Indig. "Every member of the Phreesia team has contributed to this achievement; I would like to congratulate them on reaching this milestone, and thank our clients for entrusting us to create a better, more engaging healthcare experience".

Fiscal Third Quarter 2022 Highlights

  • Revenue was $55.9 million in the quarter as compared to $38.5 million in the same period in the prior year, an increase of 45%.

  • Average number of provider clients was 2,097 in the quarter as compared to 1,737 in the same period in the prior year, an increase of 21%.

  • Average revenue per provider client was $19,299 in the quarter compared to $17,490 in the same period in the prior year, an increase of 10%.

  • Adjusted EBITDA was negative $17.6 million in the quarter compared to positive $1.2 million in the same period in the prior year, reflecting increased growth investment.

  • Cash and cash equivalents as of October 31, 2021 was $400.4 million, an increase of $181.6 million compared to January 31, 2021, driven primarily by our follow-on offering of common stock, which generated net proceeds of $245.8 million, partially offset by cash used for operating activities, capital expenditures and payments of finance leases and other debt.

Outlook for Fiscal 2022

We are increasing our revenue outlook for Fiscal Year 2022 to $211 million from our previously announced range of $195 million to $198 million. Our Adjusted EBITDA outlook for Fiscal Year 2022 is negative $64 million. We expect revenue for Fiscal Year 2023 to grow in the range of 20 to 25% above Fiscal Year 2022 revenue. We also anticipate a continued acceleration in investments in Fiscal Year 2023 from Fiscal Year 2022 levels and will provide an outlook for Adjusted EBITDA for Fiscal Year 2023 when we release our full Fiscal Year 2022 results in March 2022.

Stakeholder Letter and Conference Call Information

For additional information about our quarterly results, please refer to our Quarterly Stakeholder Letter that was furnished with our Form 8-K, which was filed with the SEC and can be found at https://ir.phreesia.com/resources/quarterly-stakeholder-letter/default.aspx. The Company will hold a conference call on Thursday, December 9, 2021, at 8:45 a.m. Eastern Time to review the Company’s third fiscal quarter financial results. To participate in the Company’s live conference call and webcast, please dial (866) 211-4557 (or (647) 689-6750 for international participants) using conference code number 7489917 or visit the "Events & Presentations" section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Recent Events

Addition of Insignia Health, LLC to Phreesia

On December 3, 2021, Phreesia entered into an agreement to acquire Insignia Health, LLC, a founder-led and mission-oriented company, for $35 million in cash, subject to customary purchase price adjustments. We acquired the company from its founders, the University of Oregon and its other holders of membership interest. We have closely followed Insignia for several years, and long admired the company's background in academic research and its commitment to improving health outcomes through an extensively validated approach to helping patients become more active and successful managers of their health.

COVID-19

In March 2020, the World Health Organization declared the ongoing outbreak of a novel strain of coronavirus ("COVID-19") a pandemic. There continues to be uncertainty as to the duration and extent to which the global COVID-19 pandemic, as well as the emergence of new variants, may adversely impact the Company's business operations, financial performance, and results of operations, as well as macroeconomic conditions, at this time.

Phreesia, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)

October 31, 2021

January 31, 2021

(Unaudited)

Assets

Current:

Cash and cash equivalents

$

400,395

$

218,781

Settlement assets

16,323

15,488

Accounts receivable, net of allowance for doubtful accounts of $705 and $699 as of October 31, 2021 and January 31, 2021, respectively

35,460

29,052

Deferred contract acquisition costs

1,705

1,693

Prepaid expenses and other current assets

10,450

7,254

Total current assets

464,333

272,268

Property and equipment, net of accumulated depreciation and amortization of $50,838 and $40,148 as of October 31, 2021 and January 31, 2021, respectively

32,755

26,660

Capitalized internal-use software, net of accumulated amortization of $29,838 and $25,476 as of October 31, 2021 and January 31, 2021, respectively

14,079

10,476

Operating lease right-of-use assets

2,005

2,654

Deferred contract acquisition costs

2,456

1,248

Intangible assets, net of accumulated amortization of $907 and $525 as of October 31, 2021 and January 31, 2021, respectively

2,343

2,725

Deferred tax asset

150

658

Goodwill

8,211

8,307

Other assets

2,795

1,670

Total assets

$

529,127

$

326,666

Liabilities and Stockholders’ Equity

Current:

Settlement obligations

$

16,323

$

15,488

Current portion of finance lease liabilities and other debt

4,597

4,864

Current portion of operating lease liabilities

1,116

1,087

Accounts payable

11,602

4,389

Accrued expenses

18,885

18,324

Deferred revenue

12,434

10,838

Total current liabilities

64,957

54,990

Long-term finance lease liabilities and other debt

5,134

6,471

Operating lease liabilities, non-current

1,117

1,899

Total liabilities

71,208

63,360

Commitments and contingencies

Stockholders’ Equity:

Common stock, $0.01 par value - 500,000,000 shares authorized as of both October 31, 2021 and January 31, 2021; 51,289,020 and 44,880,883 shares issued as of October 31, 2021 and January 31, 2021, respectively

513

449

Additional paid-in capital

849,450

579,599

Accumulated deficit

(383,487)

(311,777)

Treasury stock, at cost, 157,612 and 99,520 shares at October 31, 2021 and January 31, 2021, respectively

(8,557)

(4,965)

Total Stockholders’ Equity

457,919

263,306

Total Liabilities and Stockholders’ Equity

$

529,127

$

326,666

Phreesia, Inc.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share data)

Three months ended October 31,

Nine months ended October 31,

2021

2020

2021

2020

Revenue:

Subscription and related services

$

24,365

$

17,468

$

69,069

$

50,196

Payment processing fees

16,111

12,917

49,061

36,452

Life sciences

15,439

8,079

37,083

20,221

Total revenues

55,915

38,464

155,213

106,869

Expenses:

Cost of revenue (excluding depreciation and amortization)

11,644

6,472

30,210

16,477

Payment processing expense

9,449

7,530

28,822

21,125

Sales and marketing

32,036

10,481

69,215

30,013

Research and development

15,273

5,732

34,770

16,267

General and administrative

18,021

10,370

46,936

28,721

Depreciation

3,719

2,447

10,717

7,125

Amortization

1,513

1,546

4,744

4,531

Total expenses

91,655

44,578

225,414

124,259

Operating loss

(35,740)

(6,114)

(70,201)

(17,390)

Other (expense) income, net

(114)

62

(138)

(229)

Interest (expense) income, net

(311)

(467)

(756)

(1,206)

Total other expense, net

(425)

(405)

(894)

(1,435)

Loss before provision for income taxes

(36,165)

(6,519)

(71,095)

(18,825)

Provision for income taxes

(178)

(194)

(615)

(371)

Net loss

$

(36,343)

$

(6,713)

$

(71,710)

$

(19,196)

Net loss per share attributable to common stockholders, basic and diluted

$

(0.71)

$

(0.17)

$

(1.44)

$

(0.51)

Weighted-average common shares outstanding, basic and diluted

51,020,271

38,511,370

49,943,049

37,855,503

Phreesia, Inc.
Unaudited Consolidated Statements of Cash Flows
(in thousands)

Nine months Ended October 31,

2021

2020

Operating activities:

Net loss

$

(71,710)

$

(19,196)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

15,461

11,656

Stock-based compensation expense

25,976

9,616

Amortization of deferred financing costs and debt discount

216

318

Cost of Phreesia hardware purchased by customers

449

604

Deferred contract acquisition costs amortization

1,709

2,280

Non-cash operating lease expense

730

1,228

Change in fair value of contingent consideration liabilities

209

Deferred tax asset

508

279

Changes in operating assets and liabilities:

Accounts receivable

(6,408)

(5,616)

Prepaid expenses and other assets

(5,686)

(1,940)

Deferred contract acquisition costs

(2,929)

(1,901)

Accounts payable

9,490

(2,300)

Accrued expenses and other liabilities

(5,563)

3,982

Lease liability

(779)

(1,419)

Deferred revenue

1,596

1,222

Net cash used in operating activities

(36,731)

(1,187)

Investing activities:

Capitalized internal-use software

(7,962)

(4,663)

Purchase of property and equipment

(16,596)

(6,440)

Net cash used in investing activities

(24,558)

(11,103)

Financing activities:

Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions

245,813

174,800

Proceeds from issuance of common stock upon exercise of stock options

4,062

3,351

Treasury stock to satisfy tax withholdings on stock compensation awards

(3,546)

(869)

Payment of offering costs

(226)

Proceeds from employee stock purchase plan

1,147

Insurance financing agreement

2,009

Finance lease payments

(3,175)

(1,797)

Principal payments on financing agreements

(873)

(881)

Debt issuance costs

(69)

Loan facility fee payment

(125)

(225)

Payment of contingent consideration for acquisitions

(400)

Net cash provided by financing activities

242,903

176,093

Net increase in cash and cash equivalents

181,614

163,803

Cash and cash equivalents – beginning of period

218,781

90,315

Cash and cash equivalents – end of period

$

400,395

$

254,118

Supplemental information of non-cash investing and financing information:

Right-of-use assets obtained in exchange for operating lease liabilities

$

81

$

4,420

Property and equipment acquisitions through finance leases

$

2,645

$

6,050

Capitalized software acquired through vendor financing

$

$

174

Cashless transfer of term loan and related accrued fees into increase in debt balance

$

$

20,257

Cashless transfer of lender fees through increase in debt balance

$

$

406

Deferred offering costs included in accounts payable and accrued liabilities

$

$

64

Purchase of property and equipment and capitalized software included in accounts payable

$

1,082

$

1,681

Capitalized stock-based compensation

$

279

$

Cash payments for:

Interest

$

578

$

1,047

Non-GAAP financial measures

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We define Adjusted EBITDA as net income or loss before interest expense (income), net, provision for income taxes, depreciation and amortization, and before stock-based compensation expense, change in fair value of contingent consideration liabilities and other expense (income), net.

We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Annual Report on Form 10-K because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. Phreesia has not reconciled its Adjusted EBITDA outlook to GAAP Net income (loss) because it does not provide an outlook for GAAP Net income (loss) due to the uncertainty and potential variability of Other income, net and Provision for (benefit from) income taxes, which are reconciling items between Adjusted EBITDA and GAAP Net income (loss). Because Phreesia cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP Net income (loss).

Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

  • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;

  • Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; or (4) Interest expense (income), net; and

  • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss for each of the periods indicated:

Phreesia, Inc.
Adjusted EBITDA
(Unaudited)

Three months ended October 31,

Nine months ended October 31,

(in thousands)

2021

2020

2021

2020

Net loss

$

(36,343)

$

(6,713)

$

(71,710)

$

(19,196)

Interest expense (income), net

311

467

756

1,206

Provision for income taxes

178

194

615

371

Depreciation and amortization

5,232

3,993

15,461

11,656

Stock-based compensation expense

12,929

3,316

25,976

9,616

Change in fair value of contingent consideration liabilities

209

Other expense (income), net

114

(62)

138

229

Adjusted EBITDA

$

(17,579)

$

1,195

$

(28,555)

$

3,882

Phreesia, Inc.
Reconciliation of GAAP and Adjusted Operating Expenses
(Unaudited)

Three months ended October 31,

Nine months ended October 31,

(in thousands)

2021

2020

2021

2020

GAAP operating expenses

General and administrative

$

18,021

$

10,370

$

46,936

$

28,721

Sales and marketing

32,036

10,481

69,215

30,013

Research and development

15,273

5,732

34,770

16,267

Cost of revenue

11,644

6,472

30,210

16,477

$

76,974

$

33,055

$

181,131

$

91,478

Stock compensation included in GAAP operating expenses

General and administrative

$

4,943

1,635

$

11,237

$

5,169

Sales and marketing

5,169

1,008

9,046

2,530

Research and development

2,224

470

4,212

1,494

Cost of revenue

593

203

$

1,481

$

423

$

12,929

$

3,316

$

25,976

$

9,616

Adjusted operating expenses

General and administrative

$

13,078

$

8,735

$

35,699

$

23,552

Sales and marketing

26,867

9,473

60,169

27,483

Research and development

13,049

5,262

30,558

14,773

Cost of revenue

11,051

6,269

28,729

16,054

$

64,045

$

29,739

$

155,155

$

81,862

Phreesia, Inc.
Key Metrics
(Unaudited)

Three months ended October 31,

Nine months ended October 31,

2021

2020

2021

2020

Key Metrics:

Provider clients (average over period)

2,097

1,737

1,996

1,679

Average revenue per provider client

$

19,299

$

17,490

$

59,196

$

51,604

  • Provider clients. We define provider clients as the average number of healthcare provider organizations that generate revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single provider client. We believe growth in the number of provider clients is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our Platform to healthcare provider organizations that are not yet clients. While growth in the number of provider clients is an important indicator of expected revenue growth, it also informs our management of the areas of our business that will require further investment to support expected future provider client growth. For example, as the number of provider clients increases, we may need to add to our customer support team and invest to maintain effectiveness and performance of our Platform and software for our provider clients and their patients.

  • Average revenue per provider client.We define average revenue per provider client as the total subscription and related services and payment processing revenue generated from provider clients in a given period divided by the average number of provider clients that generate revenue each month during that same period. We are focused on continually delivering value to our provider clients and believe that our ability to increase average revenue per provider client is an indicator of the long-term value of the Phreesia platform.

Additional Information
(Unaudited)

Three months ended
October 31,

Nine months ended
October 31,

2021

2020

2021

2020

Patient payment volume (in millions)

$

682

$

524

$

2,079

$

1,445

Payment facilitator volume percentage

79

%

80

%

78

%

82

%

  • Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our provider clients’ businesses and the continuing shift of healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our provider clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which Phreesia acts as a gateway to other payment processors.

  • Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payment volume that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing revenue.

Available Information

Phreesia intends to use its Company website (including its Investor Relations website) as well as its Facebook, Twitter and LinkedIn accounts as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, statements about our future financial performance, including our revenue, cash flows, costs of revenue and operating expenses; our anticipated growth; our predictions about our industry; the impact of the COVID-19 pandemic on our business and our ability to attract, retain and cross-sell to healthcare provider clients; and our ability to realize the intended benefits of our acquisitions. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission ("SEC"), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2021 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures.

ABOUT PHREESIA

Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006051/en/

Contacts

Investors:
Balaji Gandhi
Phreesia, Inc.
investors@phreesia.com
(929) 506-4950

Media:
Annie Harris
Phreesia, Inc.
aharris@phreesia.com
(929) 526-2611

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting